Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative TACE + lenvatinib + tislelizumab for resectable high-risk hepatocellular carcinoma
ChiCTR2100048249Phase 2Completed
- Sponsor
- Fujian Provincial Hospital
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and tislelizumab in hepatocellular carcinoma (HCC), sponsored by Fujian Provincial Hospital. Primary endpoint: Relapse-free survival. Started Jun 2022; status: completed.
02
Drugs
lenvatinibtislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100048249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048249.